(Q39576780)

13 September 2017

0 references

Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis (English)

1 reference

13 September 2017

3

1 reference

ORCID Public Data File 2021

13 September 2017

1 reference

author name string

Thompson AE

1

1 reference

13 September 2017

Shea B

2

1 reference

13 September 2017

Fenlon D

4

1 reference

13 September 2017

Pope JE

5

1 reference

13 September 2017

1 August 2001

1 reference

13 September 2017

Arthritis & Rheumatology

1 reference

13 September 2017

44

1 reference

13 September 2017

8

1 reference

13 September 2017

1841-1847

1 reference

Identifying relevant studies for systematic reviews

13 September 2017

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200108%2944%3A8%3C1841%3A%3AAID-ART322%3E3.0.CO%3B2-8

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200108%2944%3A8%3C1841%3A%3AAID-ART322%3E3.0.CO%3B2-8

Preliminary criteria for the classification of systemic sclerosis (scleroderma)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200108%2944%3A8%3C1841%3A%3AAID-ART322%3E3.0.CO%3B2-8

Nifedipine in the treatment of Raynaud's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200108%2944%3A8%3C1841%3A%3AAID-ART322%3E3.0.CO%3B2-8

Controlled comparison of ketanserin and nifedipine in Raynaud's phenomenon

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200108%2944%3A8%3C1841%3A%3AAID-ART322%3E3.0.CO%3B2-8

Nifedipine-induced fingertip vasodilation in patients with Raynaud's phenomenon.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200108%2944%3A8%3C1841%3A%3AAID-ART322%3E3.0.CO%3B2-8

A double-blind cross-over study of nifedipine retard in patients with Raynaud's phenomenon

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200108%2944%3A8%3C1841%3A%3AAID-ART322%3E3.0.CO%3B2-8

A randomised double-blind trial of diltiazem in the treatment of Raynaud's phenomenon

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200108%2944%3A8%3C1841%3A%3AAID-ART322%3E3.0.CO%3B2-8

Clinical and rheological effects of nifedipine in Raynaud's phenomenon

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200108%2944%3A8%3C1841%3A%3AAID-ART322%3E3.0.CO%3B2-8

Nifedipine in primary Raynaud's phenomenon and in scleroderma: oral versus sublingual hemodynamic effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200108%2944%3A8%3C1841%3A%3AAID-ART322%3E3.0.CO%3B2-8

Calcium entry blocking agents in digital vasospasm (Raynaud's phenomenon)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200108%2944%3A8%3C1841%3A%3AAID-ART322%3E3.0.CO%3B2-8

Comparison of intravenous infusions of iloprost and oral nifedipine in treatment of Raynaud's phenomenon in patients with systemic sclerosis: a double blind randomised study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200108%2944%3A8%3C1841%3A%3AAID-ART322%3E3.0.CO%3B2-8

Nifedipine in the treatment of Raynaud's phenomenon in patients with systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200108%2944%3A8%3C1841%3A%3AAID-ART322%3E3.0.CO%3B2-8

Losartan therapy for Raynaud's phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200108%2944%3A8%3C1841%3A%3AAID-ART322%3E3.0.CO%3B2-8

The effects of thromboxane A2 inhibition (picotamide) and angiotensin II receptor blockade (losartan) in primary Raynaud's phenomenon

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200108%2944%3A8%3C1841%3A%3AAID-ART322%3E3.0.CO%3B2-8

10.1002/1529-0131(200108)44:8<1841::AID-ART322>3.0.CO;2-8

21 January 2018

Identifiers

DOI

1 reference

13 September 2017

1 reference